Home Cart Sign in  
Chemical Structure| 521937-07-5 Chemical Structure| 521937-07-5

Structure of CID755673
CAS No.: 521937-07-5

Chemical Structure| 521937-07-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CID-755673 is a potent and selective cell-active small molecule inhibitor for PKD with an IC50 of 182 nM and exhibits selective PKD1 inhibition when compared with AKT, PLK1, CAK, CAMKIIα, and PKC isoforms.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CID755673

CAS No. :521937-07-5
Formula : C12H11NO3
M.W : 217.22
SMILES Code : O=C1NCCCC2=C1OC3=CC=C(O)C=C32
MDL No. :MFCD03828155
InChI Key :AACFPJSJOWQNBN-UHFFFAOYSA-N
Pubchem ID :755673

Safety of CID755673

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PKD

    PKD1, IC50:180 nM

    PKD2, IC50:227 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow macrophages (BMMs) 10 μM 16 h Inhibited the motility of preosteoclasts, reducing the number of migrated cells in transwell assays. Int J Mol Sci. 2020 Feb 5;21(3):1056
Bone marrow macrophages (BMMs) 30 μM 4 days Inhibited the differentiation of committed osteoclast precursors into multinucleated mature osteoclasts, reducing the number of TRAP-positive multinucleated osteoclasts and the number of nuclei per osteoclast. Int J Mol Sci. 2020 Feb 5;21(3):1056
rat pancreatic acinar cells 25μM 3 h To test the effect of ethanol and low-dose CCK-8 on PKD1 phosphorylation and the inhibitory effect of PKD inhibitors CID or CRT. Results showed that the combination of ethanol and CCK-8 significantly enhanced PKD1 phosphorylation, and pretreatment with CID or CRT effectively inhibited this enhancement. Biochim Biophys Acta Mol Basis Dis. 2022 Nov 1;1868(11):166486
HeLa cells 5 µM 30 min Inhibition of ilimaquinone-induced Golgi fragmentation J Biol Chem. 2008 Nov 28;283(48):33516-26
LNCaP cells 50 µM 20 min Inhibition of PMA-induced PKD1 phosphorylation J Biol Chem. 2008 Nov 28;283(48):33516-26
BMM cultures 10 µM and 30 µM 5-6 days To assess the effect of PKD inhibition on maturation of multinucleated osteoclasts. Results showed that CID755673 treatment reduced the number and size of TRAP-positive multinucleated cells. J Biol Chem. 2013 Apr 5;288(14):9826-9834
bone marrow macrophages 10 µM and 30 µM 3 days To assess the effect of PKD inhibition on induction of TRAP-positive preosteoclasts. Results showed that CID755673 treatment had no significant effect on the number of TRAP-positive mononucleated cells. J Biol Chem. 2013 Apr 5;288(14):9826-9834
LNCaP prostate cancer cells 11.8 μM Inhibition of PKD1 autophosphorylation ACS Med Chem Lett. 2011 Feb 14;2(2):154-159
pancreatic acinar cells 25 µM 2 h inhibition of PKD activation and NF-κB activation Front Physiol. 2017 Dec 7;8:1014
LNCaP cells 11.8 µM 20 min Evaluate the inhibitory effect of CID755673 on PKD1 autophosphorylation Pharmaceutics. 2011;3(2):186-228
Purified NK cells 5-200 μM 2 h (degranulation) and 6 h (cytokine release) To evaluate the effect of CID755673 on degranulation and cytokine release in purified NK cells. Results showed that CID755673 had a weaker effect on degranulation but significantly inhibited cytokine release at high concentrations. Additionally, significant donor variations were observed. Front Immunol. 2013 Mar 18;4:66
NK cells in human peripheral blood mononuclear cells (PBMCs) 5-100 μM 2 h (degranulation) and 6 h (cytokine release) To evaluate the effect of CID755673 on NK cell degranulation and cytokine release. Results showed that CID755673 significantly inhibited NK cell degranulation and cytokine release, with IFN-γ production almost completely abrogated. Front Immunol. 2013 Mar 18;4:66

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Alcoholic pancreatitis model Intraperitoneal injection 20mg/kg Single injection, 60 minutes before pancreatitis induction To evaluate the therapeutic effect of PKD inhibitors CID or CRT on alcoholic pancreatitis. Results showed that pretreatment with CID or CRT significantly reduced ethanol diet-enhanced PKD phosphorylation and catalytic activity, inhibited NF-κB activation and inflammatory responses, and decreased cell necrosis and the severity of pancreatitis. Biochim Biophys Acta Mol Basis Dis. 2022 Nov 1;1868(11):166486
Sprague-Dawley rats Cerulein-induced pancreatitis model Intraperitoneal injection 15 mg/kg Single dose 60 minutes prior Inhibition of PKD activation and NF-κB activation, attenuation of pancreatitis severity Front Physiol. 2017 Dec 7;8:1014

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.60mL

0.92mL

0.46mL

23.02mL

4.60mL

2.30mL

46.04mL

9.21mL

4.60mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories